mTOR Inhibitors Lower Respiratory Infection Risk

D

Dr. Joan Mannick on InsideTracker's Channel

ImmunityMedical

Quotes From Source

“People getting mTOR inhibitors reported fewer respiratory tract infections.”

Story of claim

Dr. Mannick explains mTOR inhibitors may lower respiratory infections in older adults, potentially reducing COVID-19 severity by enhancing antiviral immunity.

  • Goal: Reduce respiratory infections and COVID-19 severity using mTOR inhibitors.
  • Proof: Trials indicated fewer respiratory infections and enhanced antiviral pathways with low-dose mTOR inhibitors.
  • Nuances:
    • COVID-19 trial conducted in nursing home residents.
    • Antiviral immunity declines with age, increasing COVID-19 severity.
  • Impact on Life: Potential reduction in infection severity could lead to less frequent hospitalizations and improved quality of life.

Investments

  • Price: $50-100 per month for mTOR inhibitor medication
  • Time: Daily dosage with potential effects in a few months
  • Effort: Consistent medication intake and health monitoring

Risks

Possible immunosuppression effects; careful medical oversight required.

Alternatives

  • Flu and COVID-19 vaccinations, lifestyle modifications like regular exercise

Get Started 🚀

  • Discuss mTOR inhibitors with your doctor, especially if over 75.
  • Consider for high-risk environments like nursing homes.
  • Begin with a monitored low-dose regimen.
  • Track health improvements and infection rates.

Brogevity AI can make mistakes. Check important info.

Reference Video